Expression of Myeloid Cell Leukemia-1 (Mcl-1) Predicts the Survival of Patients with Metastatic Gastric Cancer

Esma Turkmen Bekmez,1 Gulsah Safak Orkan2

1Department of Medical Oncology, University of Health Sciences, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey
2Department of Pathology, University of Health Sciences, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey

Abstract

Objectives: The aim of this study is to investigate the effect of myeloid cell leukemia-1 expression on overall survival in metastatic gastric cancer patients.

Methods: The files of 57 metastatic gastric cancer patients who were followed up in our clinic were reviewed retrospectively. The expression of Mcl-1 in the tumor tissue was immunohistochemically examined. The level of Mcl-1 staining was given in percentage (range: 0-100%). The correlation between the clinicopathological characteristics, progression-free survival, overall survival and Mcl-1 was analyzed.

Results: Of the 57 patients in our study, 41 were male and 16 were female. The median age was 66 years. The median Mcl-1 expression value was 70. Median progression-free survival was 7.6 months, median overall survival was 9.3 months. In the multivariate analysis, Mcl-1 expression ≤70 and responsiveness to first line therapy were found to be independent good prognostic factors for overall survival, respectively (17 vs 6 months (p<0.001); 16.3 vs 8.7 months (p=0.04)). The expression of Mcl-1 was higher in pure adenocarcinoma, well-differentiated carcinoma and visceral organ metastasis (p=0.005, p=0.01, p=0.006, respectively). No relationship was found between Mcl-1 value and gender, age, smoking, performance score, Her-2/neu expression, tumor localization and omental involvement status.

Conclusion: In our study, we found that the myeloid cell leukemia-1 expression and responsiveness to first line therapy are good prognostic factors in terms of overall survival at metastatic gastric cancer patients.

Keywords: Metastatic gastric cancer, myeloid cell leukemia-1, overall survival

Cite This Article: Turkmen Bekmez E, Safak Orkan G. Expression of Myeloid Cell Leukemia-1 (Mcl-1) Predicts the Survival of Patients with Metastatic Gastric Cancer. EJMO 2020;4(4):271–277.

Worldwide, gastric cancer is the fourth most common cancer, accounting for 6 percent of total cancer incidence, and is the third leading cause of death, accounting for 8 percent of cancer-related deaths. Despite a steady decline in the rates of incidence and mortality observed worldwide for several decades, this trend has been lessened.[1] Men and women are not equally affected; incidence rates are approximately twofold higher in men than in women.[2] Surgery is still the most effective treatment for gastric cancer and good survival can be achieved if tumor is resectable. However, most gastric cancer is either diagnosed at an advanced stage or relapses after apparently curative surgery. The standard of care for patients with metastatic gastric cancer (MGC) is palliative chemotherapy with best supportive care. With the increasing use of cytotoxic chemotherapy agents in various types of cancer, chemotherapy has also been used for MGC, and various studies have demonstrated the superiority of systemic chemotherapy over best supportive care.[3–5] However, despite the established efficacy of chemotherapeutic agents, prognosis is still poor with median survival being less than 1 year.

The Bcl-2 (B-cell lymphoma-2) family of proteins, which consists of anti-apoptotic and pro-apoptotic members, is a

Address for correspondence: Esma Turkmen Bekmez, MD. Saglik Bilimleri Universitesi, Derince Egitim ve Arastirma Hastanesi, Tibbi Onkoloji Anabilim Dali, 41900, Kocaeli, Turkey
Phone: +90 262 317 80 00 E-mail: esma_a143@hotmail.com
Submitted Date: August 14, 2020 Accepted Date: October 24, 2020 Available Online Date: October 26, 2020
©Copyright 2020 by Eurasian Journal of Medicine and Oncology - Available online at www.ejmo.org
OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
critical regulator for the mitochondrial pathway of apoptosis through controlling the integrity of the outer mitochondrial membrane.\[^a\] The pro-apoptotic members control the release of cytochrome c, and subsequent activation of caspases. In contrast, anti-apoptotic members such as Bcl-2, Bcl-xL, Bcl-w, A1 and myeloid cell leukemia-1 (Mcl-1) promote cell survival by inhibiting pro-apoptotic proteins, including Bim, Bax, and Bak.\[^6–9\]

Mcl-1 is a member of the anti-apoptotic bcl-2 family of proteins, is frequently upregulated or overexpressed in malignant cells and exerts its anti-apoptotic function by heterodimerizing with other Bcl-2 family members and preventing the permeabilization of the mitochondrial outer membrane.\[^10,11\] Increased expression of Mcl-1 occurs in a variety of human cancers and is strongly associated with resistance to therapies, tumor progression, and poor prognosis in most cancers, including gastric cancer.\[^12–17\]

In our study, the expression of Mcl-1 was investigated for clinicopathological and prognostic significance in patients with metastatic gastric carcinoma.

### Methods

The study included 57 patients with metastatic gastric cancer. Local ethics committee approval was obtained for study. Clinicopathological characteristics, treatments administered, and treatment responses were retrospectively recorded from the patient files. Progression-free Survival (PFS) was considered as the time from diagnosis to progression and overall survival (OS) was considered as the time from diagnosis to death or last follow-up. The expression of Mcl-1 was immunohistochemically examined in the tissue biopsy of patients at the time of diagnosis (endoscopic material or gastrectomy material). For immunohistochemical analysis, we used formalin-fixed and paraffin-embedded specimens. Cut sections to 4 μm and dry at 80°C for 15 min. Dilute anti-Mcl-1 polyclonal antibody (sc-74437; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:50–1:100 (antibody diluent from Ventana) and fill into a Ventana antibody dispenser. The Ventana staining procedure includes pretreatment with Cell Conditioner 2 (pH 6) for 60 min (standard), followed by incubation with 1:50–1:100 diluted antibody at 37°C for 32 min. Upon antibody incubation perform Ventana standard signal amplification, ultraWash, counter-staining with one drop of Hematoxylin for 4 min and one drop of bluing reagent for 4 min. For chromogenic detection use ultraView Universal DAB Detection Kit (Ventana). Remove slides from stainer, wash in water with a drop of dishwashing detergent and mount. Stained tissues were viewed and photographed using a light microscope (Olympus, Tokyo, Japan). The staining pattern was evaluated in percentage (0%=no staining; 100%=high staining). Statistical analysis was performed with the Statistical Package for the Social Sciences 17. The expression of Mcl-1 with relation to various clinicopathological

### Table 1. Correlation between Mcl-1 expression and clinicopathological parameters of gastric cancer

| Variables                  | MCL high (>70) (n) | MCL low (≤70)(n) | p    |
|----------------------------|--------------------|------------------|------|
| Gender                     |                    |                  |      |
| Male                       | 31                 | 10               | 0.1  |
| Female                     | 12                 | 14               |      |
| Age                        |                    |                  |      |
| ≥65                        | 24                 | 6                | 0.39 |
| <65                        | 19                 | 8                |      |
| Grade                      |                    |                  |      |
| Differantiated             | 29                 | 4                | 0.01 |
| Undifferantiated           | 14                 | 10               |      |
| Localization               |                    |                  |      |
| Proximal                   | 30                 | 12               | 0.31 |
| Distal                     | 13                 | 2                |      |
| Primary operated           |                    |                  |      |
| Yes                        | 8                  | 5                | 0.27 |
| No                         | 35                 | 9                |      |
| Her-2/neu status           |                    |                  |      |
| Negative                   | 14                 | 7                | 0.5  |
| Positive                   | 8                  | 2                |      |
| Unknown                    | 21                 | 5                |      |
| Smoking history            |                    |                  |      |
| Yes                        | 18                 | 8                | 0.31 |
| No                         | 25                 | 6                |      |
| ECOG performance           |                    |                  |      |
| 0–1                        | 29                 | 12               | 0.3  |
| ≥2                         | 14                 | 2                |      |
| Response to first line therapy |               |                  |      |
| Yes                        | 14                 | 6                | 0.1  |
| No                         | 19                 | 6                |      |
| 5Fu/oxaliplatin treatment  |                    |                  |      |
| Yes                        | 14                 | 6                | 0.5  |
| No                         | 29                 | 8                |      |
| 5Fu/cisplatin treatment    |                    |                  |      |
| Yes                        | 9                  | 5                | 0.29 |
| No                         | 34                 | 9                |      |
| Visseral metastasis        |                    |                  |      |
| Yes                        | 30                 | 4                | 0.006|
| No                         | 13                 | 10               |      |
| Histology                  |                    |                  |      |
| Signet ring cell           | 5                  | 7                | 0.005|
| Pure adenocarcinoma        | 38                 | 7                |      |
| Omental involved           |                    |                  |      |
| Yes                        | 10                 | 7                | 0.06 |
| No                         | 33                 | 7                |      |

Mcl-1: Myeloid cell leukemia-1; ECOG: Eastern Cooperative Oncology Group.
parameters was assessed with the $X^2$ test and Fisher's exact test. The survival rates of patients was estimated with the Kaplan-Meier method and analyzed using a log-rank test. Differences were considered significant when $p<0.05$.

**Results**

The study included 57 patients. All patients were in the metastatic stage at the time of diagnosis. Of the patients, 41 were male and 16 were female. The median age was 66
Table 3. Univariate and multivariate analysis for OS

| Variables                          | Number of patients n (%) | Univariate analysis for OS (month) | p (univariate) | Multivariate analysis |
|------------------------------------|--------------------------|-----------------------------------|----------------|-----------------------|
| Gender                             |                          |                                   |                |                       |
| Male                               | 41 (71.9)                | 9.3                               | 0.34           |                       |
| Female                             | 16 (28.1)                | 8.9                               |                |                       |
| Age                                |                          |                                   |                |                       |
| ≥65                                | 30 (47.4)                | 9.1                               | 0.8            |                       |
| <65                                | 27 (52.6)                | 9.3                               |                |                       |
| Grade                              |                          |                                   |                |                       |
| Differantiated                     | 33 (57.9)                | 9.3                               | 0.48           |                       |
| Undifferantiated                   | 24 (42.1)                | 9                                 |                |                       |
| Histology                          |                          |                                   |                |                       |
| Signet ring cell                   | 12 (21.1)                | 8.2                               | 0.98           |                       |
| Pureadenocarcinoma                 | 45 (78.9)                | 9.3                               |                |                       |
| Localization                       |                          |                                   |                |                       |
| Proximal                           | 42 (73.7)                | 9.1                               | 0.34           |                       |
| Distal                             | 15 (26.3)                | 10.2                              |                |                       |
| Primary operated                   |                          |                                   |                |                       |
| Yes                                | 13 (22.8)                | 15.4                              | 0.24           |                       |
| No                                 | 44 (77.2)                | 8.9                               |                |                       |
| Her-2/neu status                   |                          |                                   |                |                       |
| Negative                           | 21 (36.8)                | 13.6                              | 0.03           | NS                    |
| Positive                           | 10 (17.5)                | 8.2                               |                |                       |
| Unknown                            | 26 (45.6)                | 4.4                               |                |                       |
| Smoking history                    |                          |                                   |                |                       |
| Yes                                | 26 (45.6)                | 9.1                               | 0.39           |                       |
| No                                 | 31 (54.4)                | 9.3                               |                |                       |
| ECOG performance                   |                          |                                   |                |                       |
| 0–1                                | 41 (71.9)                | 9.1                               | 0.3            |                       |
| ≥2                                 | 16 (28.1)                | 4.9                               |                |                       |
| Response to first line therapy     |                          |                                   |                |                       |
| Yes                                | 22 (38.6)                | 17                                | <0.001         |                       |
| No                                 | 35 (61.4)                | 6                                 |                |                       |
| 5Fu/cisplatin treatment            |                          |                                   |                |                       |
| Yes                                | 14 (24.6)                | 15.4                              | 0.009          | NS                    |
| No                                 | 43 (75.4)                | 8.7                               |                |                       |
| Oxaliplatin treatment              |                          |                                   |                |                       |
| Yes                                | 20 (35.1)                | 9.3                               | 0.43           |                       |
| No                                 | 37 (64.9)                | 8.6                               |                |                       |
| Visseral metastasis                |                          |                                   |                |                       |
| Yes                                | 34 (59.6)                | 9.3                               | 0.86           |                       |
| No                                 | 23 (40.4)                | 9                                 |                |                       |
| Omental involved                   |                          |                                   |                |                       |
| Yes                                | 17 (29.8)                | 8.9                               | 0.4            |                       |
| No                                 | 40 (70.2)                | 9.6                               |                |                       |
| Mcl-1 status                       |                          |                                   |                |                       |
| Low                                | 14 (24.6)                | 16.3                              | 0.01           |                       |
| High                               | 43 (75.4)                | 8.7                               |                |                       |

Mcl-1: Myeloid cell leukemia-1; ECOG: Eastern Cooperative Oncology Group; NS: Nonsignificant; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval.
years. The median progression-free survival (PFS) and overall survival (OS) were 7.6 months and 9.3 months respectively. The median Mcl-1 value was 70%. The comparison of the Mcl-1 levels and clinicopathological characteristics showed that the expression of Mcl-1 was higher in the patients with pure adenocarcinoma histology, well differentiated carcinoma and visceral organ metastasis (Mcl-1>70) (Table 1).

The PFS was 8.6 months in the patients with a low Mcl-1 level (Mcl-1≤70), while it was 7 months in the patients with a high Mcl-1 level (p=0.02) (Table 2).

According to the univariate and multivariate analysis, the patients, who responded to the first-line treatment and who had low Mcl-1 levels had longer overall survival [17 vs. 6 months (p<0.001); 16.3 vs. 8.7 months respectively (p=0.04)] (Table 3).

Mcl-1 was found to be an independent good prognostic factor for both PFS and OS (Figs. 1, 2).

Discussion

In the last decade, the development of targeted therapies and the optimization of already available chemotherapeutic drugs has expanded the available treatment options for advanced gastric cancer and granted better survival expectations to the patients. Although expression of different biomarkers, such as tumor EBV, MSI, PD-L1 and Her-2/neu status are associated with both prognosis and treatment response of certain agents, there is limited biomarker for predicting prognosis of patients with gastric cancer. This study has shown that; a Mcl-1 level of ≤70 improved PFS and OS. The favorable outcome in patients with low Mcl-1 expression suggests that this marker can be used as an emerging biomarker.

Apoptosis, or programmed cell death, is critical for tissue homeostasis and normal development, and its dysregulation plays a major role in the development of cancer. Moreover, compromised apoptosis is directly associated with resistance to cytotoxic agents as well as to targeted therapies. The Bcl-2 family of proteins are key regulators of apoptosis. Mcl-1 protein is a member of the Bcl-2 protein family. It inhibits apoptosis, and overexpression of Mcl-1 has been associated with tumor progression and resistance to both traditional and targeted therapy, including Bcl-2 inhibitors. Mcl-1 is highly expressed in a variety of human cancers. Furthermore, expression of Mcl-1 is associated with advanced stages and poor clinical outcome of many human cancers including gastric cancer. For example, cholangiocarcinoma cells upregulate Mcl-1 expression via the interleukin-6-mediated Stat3 pathway. In gastric cancer, the Mcl-1 level was evaluated by an immunohistochemical technique, and the expression level of Mcl-1 was suggested as a prognostic marker. This study showed that an Mcl-1 expression of ≤70 improved PFS and OS. The favorable outcome in patients with low Mcl-1 expression suggests that Mcl-1 may be used as an emerging biomarker.

In this study, the level of Mcl-1 was immunohistochemically examined in tumor tissue of patients with metastatic gastric cancer. The levels of Mcl-1 staining were given in percentages. The median Mcl-1 value was 70%. The patients were divided into two groups based on the median value: high Mcl-1 (>70) and low Mcl-1 (≤70). The comparison of the clinicopathological characteristics showed that the Mcl-1 level was relatively higher in differentiated tumors with no signet-ring cell component (pure adenocarcinoma-
In conclusion, our study suggests that mcl-1 plays an important role in metastatic gastric cancer progression by modulating tumor cell proliferation. It may be used as a molecular marker for the prediction of clinical outcomes at metastatic gastric cancer patients.

The small sample size and retrospective design were the limitations of our study. Unknown HER-2 expression status of some patients was another limitation of our study. The small sample size and retrospective design were the limitations of our study. Unknown HER-2 expression status of these patients.

Overall survival was better in the low Mcl-1 group. A Mcl-1 level of ≤70 was a good prognostic factor for overall survival. According to the literature, studies to date have evaluated the Mcl-1 level in operated gastric cancer patients and the positive Mcl-1 expression has been evaluated to be associated with poor prognosis. In our study, all patients were in the metastatic stage. Only one patient had an Mcl-1 expression level of 0%. Survival was poorer in the patients with an Mcl-1 expression of >70. This result suggested that the Mcl-1 expression may be a potential therapeutic target and Mcl-1-inhibiting agents may be used for the treatment of these patients.

The small sample size and retrospective design were the limitations of our study. Unknown HER-2 expression status of some patients was another limitation of our study. In conclusion, our study suggests that mcl-1 plays an important role in metastatic gastric cancer progression by modulating tumor cell proliferation. It may be used as a molecular marker for the prediction of clinical outcomes at metastatic gastric cancer patients.

Disclosures

Ethics Committee Approval: The ethics committee of University of Health Sciences Kocaeli Derince Training and Research Hospital provided the ethics committee approval for this study (11.06.2020-2020/20).

Peer-review: Externally peer-reviewed.

Conflict of Interest: None declared.

Authorship Contributions: Concept – E.T.B.; Design – E.T.B.; Supervision – E.T.B.; Materials – E.T.B., G.S.O.; Data collection &/or processing – E.T.B., G.S.O.; Analysis and/or interpretation – G.S.O.; Literature search – G.S.O.; Writing – E.T.B.; Critical review – E.T.B.

References

1. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 2014;50:1330–44.
2. Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer 2001;84:400–5.
3. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163–8.
4. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epirubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587–91.
5. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37–41.
6. Ola MS, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 2011;351:41–58.
7. Llambi F, Green DR. Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev 2011;21:12–20.
8. Weyhenmeyer B, Murphy AC, Prehn JH, Murphy BM. Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Exp Oncol 2012;34:192–9.
9. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012;30:3127–35.
10. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 1993;90:3516–20.
11. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010;584:2981–9.
12. Zhang T, Zhao C, Luo L, Zhao H, Cheng J, Xu F. The expression of Mcl-1 in human cervical cancer and its clinical significance. Med Oncol 2012;29:1985–91.
13. Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao Y, et al. MIR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance. Med Oncol 2012;29:1681–6.
14. Henderson-Jackson EB, Helm J, Ghayouri M, Hakam A, Nasir A, Leon M, et al. Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int J Clin Exp Pathol 2010;3:768–74.
15. Likui W, Qun L, Haiming Y, Xiaojun L, Xiaojun L. Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. J Surg Oncol 2009;100:396–400.
16. Maeta Y, Tsujitani S, Matsumoto S, Yamaguchi K, Tatebe S, Kondo A, et al. Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma. Gastric Cancer 2004;7:78–84.
17. Tsujitani S, Saito H, Watatsuki T, Ikeguchi M, Shirabe K, Morita M, et al. Relationship between expression of apoptosis-relat-
ed proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today 2012;42:225–32.
18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
19. Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ 2018;25:56–64.
20. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015;6:e1590.
21. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005;42:1329–38.
22. Jiang CC, Lucas K, Avery-Kiejda KA, Wade M, deBock CE, Thorne RF, et al. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res 2008;68:6708–17.
23. Akagi H, Higuchi H, Sumimoto H, Igarashi T, Kabashima A, Mizuguchi H, et al. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer 2013;16:100–10.